LDN for Complex Regional Pain Syndrome: Burning Pain, Function, Opioid Safety, and GLP-1 Coordination

 

Burning pain. Severe sensitivity to light touch. Swelling. Temperature or color changes. Stiffness, weakness, tremor, or dystonia. Complex regional pain syndrome, commonly called CRPS, can affect far more than pain intensity. It can change how a limb feels, moves, functions, and responds to ordinary activity.

That is why a treatment discussion cannot be reduced to a single pain score.

Low-dose naltrexone, commonly called LDN, is increasingly discussed as a non-opioid option for CRPS. The interest has a real research foundation, but the direct evidence remains early. A 2013 publication described two people treated with LDN as part of broader CRPS care. A 2016 case report described one adolescent with marked pain improvement. Later retrospective chronic-pain studies reported that some patients with CRPS or neuropathic pain responded to LDN.

Those reports are signals, not proof.

Case reports cannot separate the effect of LDN from concurrent treatment, natural symptom fluctuation, rehabilitation, expectation, or other clinical changes. Retrospective chart reviews lack randomization and placebo control. Two registered CRPS studies are designed to add better evidence, but trial registration and recruitment are not treatment results.

The responsible conclusion is straightforward: LDN may be considered by some clinicians as an off-label component of an individualized CRPS plan, but it has not been proven to reverse CRPS, restore a limb, stop spread, eliminate allodynia, or replace functional rehabilitation and multidisciplinary care.

Considering LDN for a defined CRPS symptom or functional goal? Explore Scripx low-dose naltrexone options, review LDN medication interactions, or contact Scripx for a pharmacist-supported medication discussion. LDN is off label for CRPS. Current opioid, tramadol, buprenorphine, methadone, cough medicine, and planned-procedure exposure must be reviewed before naltrexone is considered.

 

The Direct Answer: Is LDN Proven for CRPS?

No. LDN is not FDA approved for CRPS, and no completed CRPS-specific randomized placebo-controlled result has established that it reliably reduces pain, restores function, improves dystonia, or changes the disease course.

The most useful way to understand the evidence is to separate four layers:

1. Published CRPS case reports describe individual responses.

2. Retrospective chronic-pain cohorts identify possible responder patterns.

3. Registered prospective trials show that the question is being studied.

4. CRPS guidelines emphasize functional restoration and coordinated multidisciplinary care, not reliance on one medication.

Each layer adds information, but none currently supports a predictable individual outcome.

What CRPS Is, and Why Diagnosis Matters

CRPS usually affects a limb after an injury, fracture, surgery, or other event, although the triggering event may be minor or unclear. Pain is typically regional and disproportionate to the expected course of the initial injury. Symptoms and signs may involve sensory, vasomotor, sweating or swelling, and motor or trophic domains.

The internationally used Budapest clinical criteria require continuing disproportionate pain, symptoms across multiple categories, observable signs across multiple categories at evaluation, and no better diagnosis that explains the presentation.

Burning pain alone does not establish CRPS. Peripheral neuropathy, nerve injury, vascular disease, infection, inflammatory arthritis, compartment problems, radiculopathy, entrapment neuropathy, and other conditions may produce overlapping symptoms. A treatment trial should not substitute for diagnostic review, particularly when weakness, wounds, major color changes, fever, or rapidly progressive symptoms are present.

The 2013 Publication Reported Two Patients, Not a Controlled Trial

The best-known direct publication is the 2013 report by Chopra and Cooper, “Treatment of Complex Regional Pain Syndrome Using Low Dose Naltrexone.”

The paper described two patients with severe, longstanding CRPS who received LDN after other approaches had not adequately controlled their symptoms. The authors reported improvements that included pain, dystonic spasms, sleep, energy, mobility, and CRPS flares.

The report is clinically interesting, but several limitations are essential:

• It included only two people.

• There was no placebo or untreated comparison.

• LDN was used with other CRPS therapies, including ketamine-related treatment in the clinical histories.

• Outcomes were based on individual clinical courses rather than a prespecified randomized protocol.

• The report cannot show how often another patient would respond.

• It cannot establish that LDN reversed the biological processes responsible for CRPS.

The correct takeaway is not that two positive cases prove effectiveness. It is that the observations created a reason for controlled study.

The 2016 Case Report Adds One More Response, Not Generalizable Evidence

A 2016 case report described an adolescent with CRPS type I whose pain reportedly decreased from 7 out of 10 to 1 out of 10 after four weeks of LDN treatment.

That is a meaningful outcome for one patient. It is not a response rate.

Single-patient reports are especially vulnerable to co-treatment effects, changing activity, regression toward the mean, expectation, and the variable natural course of CRPS. They can generate hypotheses and help researchers define outcomes, but they cannot establish superiority to placebo or to another treatment.

Another 2016 report described improvement in a patient treated through a multimodal plan that addressed CRPS alongside small intestinal bacterial overgrowth and obstructive sleep apnea. Because several interventions changed, the contribution of LDN cannot be isolated.

Across these publications, the direct case-report literature remains tiny.

 

 

Retrospective Studies Provide a Signal, With Important Bias

A 2023 single-institution case series reviewed 137 patients who were prescribed LDN for chronic pain. Forty-four percent had no evidence of filling the prescription. Among 70 patients documented as taking LDN, 64 percent were categorized as responders. Patients with neuropathic pain or CRPS were more likely to report at least 50 percent pain relief than patients with spondylosis. In the CRPS subgroup, nine of 12 patients were categorized as responders.

That finding deserves attention, but it does not mean that 75 percent of all people with CRPS should expect the same result. The analysis was retrospective, performed at one institution, and limited by incomplete follow-up, self-reported outcomes, treatment selection, and the exclusion of many people who never appeared to start the medication.

A separate 2025 retrospective cohort from one pain physician’s practice reported subjective benefit across a mixed chronic-pain population. It was not a randomized CRPS trial, and its broader findings cannot establish CRPS-specific effectiveness.

Retrospective evidence is useful for identifying patterns and designing trials. It is weaker than a prospective randomized comparison for determining whether a treatment caused an outcome.

Two Registered Trials Matter, but Registration Is Not a Result

Two CRPS studies make this topic more timely.

The Stanford study, NCT02502162, is designed as a randomized placebo-controlled study of LDN for CRPS symptom relief. Its registry lists a target enrollment of 120 participants. As of this review, the study remained active and had no posted efficacy results.

The Hospital for Special Surgery feasibility study, NCT06306157, plans to enroll 40 participants and collect preliminary information on pain, symptom severity, and side effects. HSS continues to list it among its active CRPS clinical research.

These trials are encouraging because they move the question beyond anecdote. They do not yet answer it.

Until results are available, reviewed, and placed in context, neither registry record should be described as proof that LDN works for CRPS.

Pain Relief Is Not the Same as CRPS Reversal

CRPS outcomes should be separated rather than bundled into a general claim of “improvement.”

A person may report lower pain without recovery of range of motion. Sleep may improve while allodynia remains. A limb may move more easily without normalization of temperature, color, sweating, edema, weakness, tremor, or dystonia. Better participation in therapy is not the same as disease modification.

Current evidence does not establish that LDN:

• Reverses CRPS

• Repairs injured nerves

• Normalizes autonomic function

• Reverses trophic skin, hair, nail, bone, or tissue changes

• Prevents spread to another limb

• Prevents recurrence after a procedure or new injury

• Reliably resolves allodynia, weakness, tremor, or dystonia

• Restores work capacity or long-term independence

If LDN is considered, pain intensity should be only one part of monitoring. Function, sleep, touch tolerance, range of motion, activity, therapy participation, medication burden, adverse effects, and patient-defined goals should be tracked separately.

Functional Restoration Remains Central to CRPS Care

The fifth-edition CRPS guidelines emphasize interdisciplinary care and functional restoration. The National Institute of Neurological Disorders and Stroke also identifies physical therapy and gentle movement as important components of treatment.

Depending on the individual, a coordinated plan may involve:

• Physical or occupational therapy

• Graded movement and desensitization

• Range-of-motion, strength, and functional training

• Graded motor imagery or mirror-based approaches

• Psychological support for coping, sleep, fear of movement, and participation

• Neuropathic-pain medications or topical therapies

• Procedures or neuromodulation for selected patients

• Treatment of bone health, sleep, mood, or other contributing conditions

Medication can sometimes make rehabilitation more tolerable. It does not replace the rehabilitation goal.

A claim that LDN “restores function” should therefore be based on measured functional outcomes, not inferred from a pain score or an isolated testimonial.

Opioid Exposure Is a Critical Safety Gate

Naltrexone is an opioid antagonist. Even when prescribed at a lower dose, its opioid-receptor activity makes current opioid exposure clinically important.

Current naltrexone labeling warns that naltrexone can block opioid effects and precipitate withdrawal in an opioid-dependent person. The approved label addresses standard-dose naltrexone, but the underlying conflict is directly relevant when clinicians evaluate LDN.

The medication review should include:

• Hydrocodone, oxycodone, morphine, fentanyl, codeine, or other opioid analgesics

• Tramadol

• Buprenorphine or methadone

• Opioid-containing cough or diarrhea medicines

• Recent emergency-department treatment

• Planned injections, sedation, surgery, dental procedures, or postoperative pain management

• Rescue plans for a severe CRPS flare or new injury

Patients should not stop an opioid or start naltrexone on their own. The transition can require a clinician-directed opioid-free interval, withdrawal-risk assessment, and an alternative pain plan.

LDN should also not be described simply as an “opioid replacement.” It may conflict with opioid therapy, but evidence has not established that it provides equivalent analgesia or function.

Procedures and Emergency Pain Plans Need Advance Coordination

CRPS patients may undergo nerve blocks, infusions, neuromodulation procedures, orthopedic care, dental treatment, or emergency evaluation. Some of these situations may involve opioid analgesia or sedation.

A routine intake should document:

• The prescriber managing LDN

• The pain specialist managing CRPS

• Current and recent opioid exposure

• Planned procedures and expected analgesia

• Whether and when LDN should be held

• How acute pain will be treated

• When LDN may be restarted

There is no universal internet schedule that safely fits every procedure, dose, formulation, or patient. Coordination must come from the clinicians managing anesthesia, pain, and the prescription.

Where the LDN Research Trust Fits

The LDN Research Trust can be useful for patient education, clinician interviews, conference material, and research discovery. Its hosted copy of the 2013 CRPS case report helps readers locate the original publication, and its chronic-pain educational material reflects ongoing clinical interest.

The Trust does not change the design of the underlying evidence. A two-person case report remains a two-person case report, even when it is widely discussed. Patient stories can illustrate lived experience, but they cannot establish a response rate, comparative benefit, or safety profile.

For clinical claims, Trust material should be paired with the original publication, ClinicalTrials.gov record, professional guideline, or current drug labeling.

The GLP-1 Crossover: A Separate Indication, Not a CRPS Treatment

Semaglutide or tirzepatide may be prescribed for a separate approved metabolic indication. Neither medication is an established CRPS treatment, and there is no clinical evidence that combining LDN with a GLP-1 medicine reverses CRPS or improves weight loss beyond the effect of appropriately indicated metabolic therapy.

The practical crossover is medication and function coordination.

Gastrointestinal effects and hydration can affect rehabilitation

Current Wegovy and Zepbound labeling identifies nausea, vomiting, diarrhea, constipation, delayed gastric emptying, and volume-depletion concerns. For someone already managing pain, sweating changes, dizziness, limited mobility, poor sleep, or reduced appetite, those effects can complicate hydration, nutrition, medication tolerance, and participation in therapy.

Weight change can alter function without treating CRPS

Improved metabolic health or lower mechanical load may help some people move more comfortably. That does not establish a direct effect on CRPS pain pathways, autonomic changes, or disease progression.

Oral medication timing may become harder to interpret

Delayed gastric emptying can affect the timing of oral medication absorption. When several medicines are started or adjusted together, it becomes difficult to identify which change caused nausea, fatigue, dizziness, sleep disruption, or altered pain.

Retatrutide remains investigational

Retatrutide remains investigational and is not FDA approved. FDA states that retatrutide cannot be used in compounding under federal law. It should not be marketed as a CRPS, pain, or weight-management treatment available through compounding.

Personalized Compounding Does Not Prove a Better Outcome

A compounding pharmacy may prepare a patient-specific LDN strength or dosage form when a valid prescription and clinical need support it. That flexibility can help implement an individualized prescription.

It does not prove that compounded LDN is FDA approved, more effective, safer, or superior to another formulation. Nor does it create evidence that a particular dose treats CRPS.

Claims should remain focused on prescription customization and pharmacist support, not on guaranteed pain relief or disease reversal.

A Responsible Monitored Trial Starts With a Defined Goal

When a clinician determines that an off-label LDN trial is reasonable, the plan should define what success means before treatment begins.

Useful baseline measures may include:

• Average and worst pain intensity

• Allodynia or touch tolerance

• Sleep quality

• Range of motion

• Walking, standing, hand use, dressing, or another relevant task

• Therapy participation

• Swelling, color, temperature, sweating, or skin changes

• Weakness, tremor, spasm, or dystonia

• Rescue medication use

• Work, caregiving, or daily-activity capacity

The plan should also specify follow-up timing, adverse-effect monitoring, stopping criteria, opioid and procedure contingencies, and who is coordinating care.

Changing LDN, a GLP-1 medicine, rehabilitation intensity, sleep medication, and another pain medicine at the same time may make the result impossible to interpret.

Symptoms That Need Prompt Evaluation

CRPS can coexist with other urgent problems. Prompt or urgent evaluation is appropriate for:

• New or rapidly progressive weakness or loss of function

• A cold, pale, blue, pulseless, or severely swollen limb

• New wound, drainage, spreading redness, fever, or concern for infection

• Sudden chest pain, shortness of breath, fainting, or signs of a blood clot

• Severe pain after a new injury or procedure

• New bladder or bowel dysfunction

• Severe vomiting, inability to maintain hydration, or severe abdominal pain

• Suspected opioid withdrawal or uncontrolled acute pain

• New neurological symptoms that do not fit the established CRPS pattern

These situations should not be managed by simply increasing or restarting LDN.

Bottom Line

LDN for CRPS is a reasonable research question, not a proven outcome.

Three case-report publications involving four patients describe individual improvement. Retrospective chronic-pain studies identify a possible responder signal, including nine responders among 12 CRPS patients in one chart review. Two registered CRPS studies are designed to provide stronger evidence. None of this currently establishes reliable pain relief, restored function, reversal of dystonia or autonomic changes, prevention of spread, or equivalence to multidisciplinary CRPS care.

For patients and clinicians, the most responsible approach is to define a measurable goal, confirm the diagnosis, protect rehabilitation, screen carefully for opioid exposure, coordinate procedures, and keep GLP-1 therapy tied to a separate metabolic indication.

Ready for a pharmacist-supported medication review? Explore Scripx low-dose naltrexone options, read the complete LDN evidence and safety guide, or contact Scripx. A prescription decision should follow individualized clinician review and should not replace CRPS rehabilitation, pain-specialist care, or urgent evaluation when symptoms change.

Educational content only. This article does not diagnose CRPS or recommend a specific medication, dose, opioid transition, or perioperative plan.

FAQ Package

1. Is LDN FDA approved for CRPS?

No. Low-dose naltrexone is used off label and is not FDA approved for complex regional pain syndrome.

2. How much direct evidence exists for LDN in CRPS?

Published direct evidence centers on a two-patient report from 2013, a single-patient report from 2016, and another multimodal case in which the LDN effect could not be isolated. Retrospective chronic-pain cohorts add uncontrolled response signals.

3. What did the 2023 retrospective study find?

Among 70 patients documented as taking LDN for chronic pain, 64 percent were categorized as responders. Nine of 12 patients in the CRPS subgroup were responders. Because the study was retrospective and uncontrolled, that subgroup result is not a reliable population response rate.

4. Are randomized trials studying LDN for CRPS?

Yes. NCT02502162 is a planned 120-person randomized placebo-controlled Stanford study, and NCT06306157 is a 40-person Hospital for Special Surgery feasibility study. No efficacy results were posted at the time of this review.

5. Can LDN cure or reverse CRPS?

No clinical evidence establishes that LDN cures CRPS, repairs nerves, reverses autonomic or trophic changes, or prevents spread or recurrence.

6. Can LDN improve dystonia or muscle spasms caused by CRPS?

Improvement was described in individual case reports, but controlled evidence has not established a reliable effect on CRPS-related dystonia or spasms.

7. Does LDN replace physical or occupational therapy?

No. CRPS guidelines emphasize functional restoration and interdisciplinary care. A medication may support participation for some patients, but it should not replace an individualized rehabilitation plan.

8. Can LDN be taken with opioid pain medicine?

Naltrexone can block opioid effects and precipitate withdrawal in an opioid-dependent person. Opioids, tramadol, buprenorphine, methadone, and opioid-containing cough medicines require prescriber review before LDN is considered.

9. What if surgery or a dental procedure is planned?

The LDN prescriber, procedural clinician, anesthesiology team, and pain clinician should coordinate the hold, acute-pain, and restart plan. Patients should not rely on a universal online schedule.

10. Do semaglutide or tirzepatide treat CRPS?

No. GLP-1 medicines may be prescribed for separate approved metabolic indications, but they are not established CRPS treatments.

11. Why do hydration and nutrition matter when CRPS and GLP-1 therapy overlap?

Nausea, vomiting, diarrhea, reduced intake, and volume depletion may worsen dizziness, fatigue, medication tolerance, and the ability to participate in rehabilitation.

12. Can a compounding pharmacy prepare patient-specific LDN?

A compounding pharmacy may prepare a patient-specific strength or dosage form when supported by a valid prescription and clinical need. Customization does not establish CRPS efficacy or make the compounded preparation FDA approved.